Mounjaro-related gastrointestinal claims are part of broader federal GLP-1 litigation, not a Mounjaro-only class action. As of September 1, 2026, the Judicial Panel on Multidistrict Litigation reported 4,022 pending actions across MDL 3094. That is an MDL-wide count involving several drugs, manufacturers, and alleged gastrointestinal injuries—not a count of Mounjaro-only or gastroparesis-only cases. Plaintiffs allege inadequate warnings and injuries; Eli Lilly denies the allegations. General causation and expert admissibility remain contested.

Mounjaro Lawsuit Status as of September 8, 2026

The litigation involving Mounjaro (tirzepatide) is centralized in the Eastern District of Pennsylvania under MDL 3094, In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation.

Key updates regarding the current status include:

• Case Count: As of September 1, 2026, there are 4,022 pending actions in the MDL.
• Rule 702 Hearing: Case Management Order 32 schedules a Rule 702 hearing for September 10–18, 2026. The hearing concerns proposed expert evidence; it is not a bellwether trial. As of September 8, it has not begun, and the court has not issued the resulting expert-admissibility rulings.
• No Global Outcomes: There has been no class certification, no global settlement agreement, and no bellwether trial verdict. Consequently, there is no established "average" payout for these claims.

Mounjaro versus the Broader GLP-1 MDL

It is important to distinguish Mounjaro from other medications involved in the same litigation. MDL 3094 covers several GLP-1 receptor agonists manufactured by different pharmaceutical companies.

Notably, litigation regarding NAION (non-arteritic anterior ischemic optic neuropathy) is handled under a separate docket, MDL 3163, and is not part of the gastrointestinal injury proceedings in MDL 3094.

What Plaintiffs Allege and What Defendants Dispute

Plaintiffs assert failure-to-warn and related product-liability theories. They allege that Eli Lilly knew or should have known of risks of severe gastrointestinal injuries and did not provide adequate warnings to patients and prescribing clinicians. Those are allegations, not findings that Mounjaro caused a particular person's condition.

On August 15, 2025, the court granted defendants' dismissal motions in part and denied them in part, while allowing amendment of some allegations. That pleading-stage opinion narrowed and preserved different theories; it did not decide general causation, individual causation, liability, or damages. Eli Lilly continues to dispute the plaintiffs' claims.

What the Current Mounjaro Label Says

The FDA-approved label for Mounjaro has evolved, but it currently contains specific language regarding gastrointestinal function:

• Delayed Gastric Emptying: The current DailyMed prescribing information states that Mounjaro delays gastric emptying.
• Gastrointestinal Adverse Reactions: The label says gastrointestinal adverse reactions are sometimes severe and that Mounjaro is not recommended in patients with severe gastroparesis.
• Warning Structure: Mounjaro's boxed warning concerns the risk of thyroid C-cell tumors. It does not contain a boxed warning for gastroparesis or stomach paralysis.

The label describes population-level safety information. It does not establish whether Mounjaro caused one patient's symptoms or diagnosis.

Symptoms, Diagnosis, and Alternative Causes

Legally supportable claims require more than just a report of symptoms. Gastroparesis is a clinical diagnosis involving the delayed movement of food from the stomach to the small intestine.

Distinguishing Symptoms from Diagnosis

Symptoms such as nausea, vomiting, feeling full soon after eating, prolonged fullness, and upper-abdominal pain can occur with gastroparesis, but they are not specific to it. According to NIDDK's diagnostic guidance, clinicians use medical history, examination, tests that measure stomach emptying, and tests that rule out an obstruction or other causes. An upper endoscopy may help exclude another problem; by itself, it does not measure gastric emptying.

The Role of Differential Diagnosis

Individual causation remains contested in pharmaceutical litigation, and defendants may argue that other factors caused the injury.

• Diabetes: NIDDK identifies diabetes as the most common known underlying cause.
• Other medications: Opioids and some other drugs can slow stomach emptying or complicate the medical record.
• Other history: Prior abdominal surgery, neurologic conditions, and cases with no identified cause may also matter to a clinician's differential diagnosis.

For a legal review, the sequence of prescriptions, dose changes, symptoms, testing, and alternative-cause evaluation may be as important as the diagnosis itself.

[justice_short_1]

Practical Claim-Readiness Checklist

If you are considering a claim, you should gather specific documentation to assist in the evaluation of your case:

• [ ] Prescription and dispensing records: Documentation showing when Mounjaro was prescribed and dispensed, including dose changes.
• [ ] Onset chronology: A detailed timeline of use, dose changes, symptoms, treatment, and any interruption or discontinuation.
• [ ] Diagnostic evidence: Gastric-emptying test results plus endoscopy, imaging, or other records used to rule out different conditions.
• [ ] Hospital/ER Records: Documentation of any acute episodes requiring emergency intervention.
• [ ] Medical history: Records concerning diabetes control, prior gastrointestinal symptoms, surgery, and other relevant conditions.
• [ ] Other medications: A dated list of drugs that may affect gastrointestinal function.
• [ ] Alternative-cause workup: Notes and test results showing what other explanations clinicians considered.
• [ ] Warnings and communications: The label version, medication guide, prescribing discussions, and messages with clinicians or pharmacies.
• [ ] Losses and expenses: Medical bills, travel costs, wage records, and documentation of other claimed losses.

What an Individual Claim Must Prove

The required elements vary by state and legal theory. A claimant may need evidence addressing:

1. Product Use: Verified use of the brand-name drug Mounjaro.
2. Injury: A documented diagnosis or other legally compensable injury and its severity.
3. Causation: Evidence supporting both the claimed medical relationship in general and Mounjaro's role in that individual's injury.
4. Warning theory: Evidence that the applicable warning was legally inadequate at the relevant time.
5. Prescribing decision: Depending on applicable law, evidence about what the prescribing clinician knew and whether an adequate warning would have changed the decision.
6. Timeliness: Filing within the deadline determined by the governing jurisdiction and facts.
7. Damages: Records connecting the claimed injury to medical costs, income loss, pain, impairment, or other recoverable harm.

[qualify_short_1]

MDL versus Class Action

The Mounjaro gastrointestinal litigation is not a certified class action. In a class action, one or more representatives litigate claims on behalf of a certified group. In an MDL, transferred cases remain individual even while common pretrial issues are coordinated.

Centralized pretrial management streamlines discovery and common motions, but it does not turn every plaintiff into a class member or merge the cases into one claim. Case Management Order 27 adopts a short-form complaint process and states that the master complaint does not merge individual claims.

[mounajro_long_1]

Compensation and Deadlines

There is no established Mounjaro settlement range or reliable "settlement calculator." Depending on the facts and applicable law, a plaintiff may claim categories such as:

• Medical expenses (past and future)
• Lost wages and diminished earning capacity
• Pain and suffering
• Permanent impairment

Claiming a category does not prove that it is recoverable or establish its value. Filing deadlines vary by state, claim type, discovery rules, and individual facts. The public MDL schedule is not a substitute for a claimant's own limitations analysis, so a prompt case-specific legal review may be important.

What Changed in 2025–2026

The litigation landscape has shifted significantly over the past 12 months:

• Pleading ruling: On August 15, 2025, the court granted dismissal motions in part and denied them in part. It did not decide causation or damages.
• Coordination and pleadings: CMO 25 addressed coordination with related cases outside the MDL, and CMO 27 adopted short-form complaints without merging individual claims.
• Streamlined docket: CMO 30 created a related streamlined docket for selected master and contested materials. That was an administrative change, not a merits ruling.
• Expert schedule: CMO 32 set the September 10–18, 2026 Rule 702 hearing. As of September 8, that hearing remains upcoming.
• Case count: JPML reported 4,022 pending MDL-wide actions as of September 1, 2026. The report does not identify how many concern Mounjaro or a particular diagnosis.

Legal.com Liability Disclaimer

All content published by Legal.com is provided for general informational purposes only. It is not legal advice, does not constitute a legal opinion, and should not be relied upon as a substitute for consultation with a qualified attorney. No attorney-client relationship is created by reading this article, using Legal.com templates, or contacting Legal.com. Legal.com disclaims all liability for actions taken or not taken based on this publication.